Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


July 06, 2015 8:05 AM ET

Biotechnology

Company Overview of Stemedica Cell Technologies, Inc.

Company Overview

Stemedica Cell Technologies, Inc., a biopharmaceutical company, engages in the development and manufacture of adult stem cells and stem cell factors for research institutions and hospitals for pre-clinical and clinical studies. The company was incorporated in 2005 and is based in San Diego, California with a subsidiary location in Lausanne, Switzerland.

5375 Mira Sorrento Place

Suite 100

San Diego, CA 92121

United States

Founded in 2005

Phone:

858-658-0910

Fax:

858-658-0986

Key Executives for Stemedica Cell Technologies, Inc.

Vice Chairman and Chief Executive Officer
Age: 68
President, Chief Medical Officer and Director
Executive Chairman
Age: 68
Chief Financial Officer
Age: 67
Chief Regulatory & Clinical Development Officer
Compensation as of Fiscal Year 2015.

Stemedica Cell Technologies, Inc. Key Developments

FDA Grants Investigational New Drug Approval for Phase IIa Clinical Trial Using Stemedica Cell Technologies, Inc.'s itMSC Therapy to Treat Alzheimer's Disease

Stemedica Cell Technologies, Inc. received the FDA's investigational new drug approval for a United States-based, Phase IIa clinical study using its allogeneic stem-cell therapy to treat subjects with mild to moderate dementia due to Alzheimer's disease (AD). The study is sponsored by Stemedica International, S.A. and will start at the University of California, San Diego (UCSD) under Principle Investigator Douglas Galasko, M.D. and expand to other sites. Stemedica International will provide management and financial support for this clinical trial. The clinical trial is titled 'A Phase IIa Multicenter, Randomized, Single-blind, Placebo-controlled, Crossover Study to Assess the Safety, Tolerability, and Preliminary Efficacy of a Single Intravenous Dose of Allogeneic Human Mesenchymal Stem Cells in Subjects with Mild to Moderate Dementia Due to Alzheimer's Disease.' Stemedica's bone marrow-derived, allogeneic itMSCs are unique because they are grown under hypoxic conditions that more closely resemble the environment in which they live in the body. Compared to other MSCs, itMSCs secrete higher levels of growth factors usually associated with angiogenesis and healing. Stemedica International's AD stem cell therapies feature itMSCs, neural stem cells (NSCs) and stem cell factors. Promising results were achieved during a three-year, intensive, pre-clinical research project supported by a grant from the Swiss Commission for Technology and Innovation (CTI). The research was conducted at the Laboratoire d'Optique Biomedicale headed by Professor Theo Lasser at École Polytechnique Fédérale de Lausanne (EPFL) in Switzerland. Stemedica International's pre-clinical research was led by Chief Scientist Tristan Bolmont, Ph.D. To evaluate the impact of an intravenous delivery of human mesenchymal stem cells on amyloid pathology, the well-established APPPS1 transgenic mouse model of Alzheimer's disease was used. Intravenous delivery of itMSC safely reduced cerebral Abeta pathology in APPPS1 animals analyzed one week after the last injection. Both aged and young APPPS1 mice exhibited significantly decreased Abeta amyloidosis following the itMSC treatments. Concomitantly, microglial activation was diminished in aged and young itMSC-treated APPPS1 mice. No increase of vascular amyloid or manifestation of microhemorrhages was observed following the repeated intravenous itMSC delivery. Biodistribution analysis revealed that intravenously delivered itMSC migrate to the brain and could be detected in this organ with the high value at one hour post-delivery, decreasing after one day and subsequently dropping below detection level at one week after the injection.

Stemedica Cell Technologies, Inc. Presents at Needham & Company's 14th Annual Healthcare Conference, Apr-14-2015 03:00 PM

Stemedica Cell Technologies, Inc. Presents at Needham & Company's 14th Annual Healthcare Conference, Apr-14-2015 03:00 PM. Venue: Westin Grand Central Hotel, New York, New York, United States.

Stemedica Cell Technologies Appoints Mahendra Rao to its Scientific and Medical Advisory Board

Stemedica Cell Technologies Inc. welcomed to its Scientific and Medical Advisory Board prominent stem cell and regenerative medicine expert Dr. Mahendra Rao, M.D., Ph.D. As a Founding Director of the National Institute of Health (NIH) Center for Regenerative Medicine (CRM), he has built the Center into a world-class organization recognized for its excellence in the clinical translation of stem cell technology, and his expertise will help Stemedica shape its strategy to meet global demand for its stem cell technology.

Similar Private Companies By Industry

Company Name Region
Avecia Biotechnology, Inc. United States
Exelixis Plant Sciences, Inc. United States
Intuitive Genomics, Inc. United States
Verichem Laboratories, Inc. United States
SG Biofuels, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Stemedica Cell Technologies, Inc., please visit www.stemedica.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.